Sprint Bioscience Ab Stock Number Of Shares Shorted
| SPRINT Stock | SEK 0.60 0.01 1.69% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Sprint Bioscience's long-term financial health and intrinsic value.
Sprint |
Sprint Bioscience AB Company Number Of Shares Shorted Analysis
Sprint Bioscience's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Sprint Bioscience AB has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Drug Manufacturers - Specialty & Generic industry. The number of shares shorted for all Sweden stocks is 100.0% higher than that of the company.
Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
Sprint Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.59 | |||
| Operating Margin | (76.00) % | |||
| Current Valuation | 24.98 M | |||
| Shares Outstanding | 69.8 M | |||
| Shares Owned By Insiders | 35.31 % | |||
| Shares Owned By Institutions | 2.59 % | |||
| Price To Earning | 32.79 X | |||
| Price To Book | 2.61 X | |||
| Price To Sales | 27.09 X | |||
| Revenue | 35.11 M | |||
| Gross Profit | 24.59 M | |||
| EBITDA | (24.22 M) | |||
| Net Income | (25.08 M) | |||
| Cash And Equivalents | 13.82 M | |||
| Cash Per Share | 1.19 X | |||
| Debt To Equity | 32.20 % | |||
| Current Ratio | 2.69 X | |||
| Book Value Per Share | 0.63 X | |||
| Cash Flow From Operations | (40.12 M) | |||
| Earnings Per Share | (0.75) X | |||
| Target Price | 32.0 | |||
| Number Of Employees | 34 | |||
| Beta | 1.32 | |||
| Market Capitalization | 53.17 M | |||
| Total Asset | 79.14 M | |||
| Retained Earnings | (39 M) | |||
| Working Capital | 4 M | |||
| Current Asset | 25 M | |||
| Current Liabilities | 21 M | |||
| Net Asset | 79.14 M |
About Sprint Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sprint Bioscience AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sprint Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sprint Bioscience AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Sprint Stock
Sprint Bioscience financial ratios help investors to determine whether Sprint Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sprint with respect to the benefits of owning Sprint Bioscience security.